Dr. Xuanming Yang Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Joint International Research Laboratory of Metabolic & Developmental Sciences, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China
Dr. Guanglei Zhuang State Key Laboratory of Oncogenes and Related Genes, Department of Obstetrics and Gynecology, Shanghai Key Laboratory of Gynecologic Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Dr. Lin Zhou
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases; Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, School of Medicine, Zhejiang University, Hangzhou, China
Dr. Vamsidhar Velcheti Cleveland Clinic, New York University School of Medicine, New York, NY, USA
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.